PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations

BackgroundImmunotherapy using programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors seems less effective in non-small cell lung cancer (NSCLC) patients with epithelial growth factor receptor (EGFR) mutations. Varied responses to PD-1/PD-L1 inhibitors have recently been ob...

Full description

Bibliographic Details
Main Authors: Tiantian Ma, Jin Jiao, Ran Huo, Xiaofang Li, Guotao Fang, Qi Zhao, Weiwei Liu, Xiao Han, Chenglin Xi, Yanan Wang, Yanhong Shang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
Non-small cell lung cancer
Epidermal growth factor receptor
Tumor immune microenvironment
Tumor mutational burden
Programmed death-ligand 1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.922899/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.922899/full

Similar Items